Full Title:

LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study

Myeloma stage or condition:

Cancer Tyrosine Kinase Mutation Breast Cancer Melanoma Multiple Myeloma Chronic Leukemia Prostate Cancer Ovarian Cancer Colorectal Cancer Lung Cancer

Study phase:

Summary/Purpose:

People with advanced chronic cancers are now living for many years as a result of new targeted anti-cancer treatments. Many of these treatments are quite new and people may take them for months, even years, as long as the treatments are helping. The purpose of this study is to help understand how to best support people receiving these treatments.

Detailed Description:

Participants ill be scheduled for an in-person, telephone or computer video interview with the researcher(s). They will be asked about their experiences receiving targeted anti-cancer treatments. Then over the next 3 months, participants will be asked to think about how receiving these cancer treatments affects daily living and to create a 'metaphor'. Metaphors may be composed with any mix of visual, verbal, musical or other works participants feel expresses and brings their experiences to life.

Treatments:

Study Arms:

Study Type:

Observational

Study Design:

Observational Model: Cohort

Time Perspective: Prospective

Recruitment status:

Recruiting

Eligibility criteria:

Inclusion Criteria:

taking chronic targeted anti-cancer agents -

Exclusion Criteria:

-

Locations / Centres:

Edith Pituskin, Edmonton, Alberta – Recruiting

Contacts:

Name: Edith Pituskin, PhD
Phone: 7804328221
Email: [email protected]

Publications:

???

First posted:

2022-12-09

Actual start date:

November 24, 2022

Last updated:

2024-04-12

Estimated enrollment:

75

Estimated completion date:

2025-05-30

Estimated primary completion date:

2024-11-30

Condition:

Cancer

Tyrosine Kinase Mutation

Breast Cancer

Melanoma

Multiple Myeloma

Chronic Leukemia

Prostate Cancer

Ovarian Cancer

Colorectal Cancer

Lung Cancer

Gender:

All

Ages:

18 Years-90 Years

Accepts healthy volunteers:

No

Listed location countries:

Canada

NCT number:

NCT05645510

Other study ID numbers:

HREBA.CC-22-0196

Has Data monitoring committee:

No

U.S. FDA-regulated product:

No

IPD Sharing Statement :

???

Responsible party:

Sponsor

Study sponsor:

collaborator
Social Sciences and Humanities Research Council of Canada
Other

lead_sponsor
University of Alberta
Other

Collaborators:

???

Investigators:

Not available

Protocol Registration and Results System:

???

Verification date:

2024-04-01